Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

NCT01281163 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

NIH

Sponsor class

Conditions

Estrogen Receptor Negative
Estrogen Receptor Positive
HER2/Neu Positive
Progesterone Receptor Negative
Progesterone Receptor Positive
Recurrent Breast Carcinoma
Stage IV Breast Cancer

Interventions

DRUG: Akt Inhibitor MK2206
OTHER: Laboratory Biomarker Analysis
DRUG: Lapatinib Ditosylate
OTHER: Pharmacogenomic Study
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)